Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Oncology|June 21, 2021
Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast CancerKelly A Hirko, Meredith M Regan, Marie C Remolano, et al.
Cancer Treatment Reviews|November 21, 2024
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and ImmunotherapyChiara Corti, Busem Binboğa Kurt, Beyza Koca, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2024
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancerPaolo Tarantino, Ogheneochuko Ajari, Noah Graham, et al.
The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.
Molecular Cancer Therapeutics|September 7, 2023
Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast CancerMaša Alečković, Zheqi Li, Ningxuan Zhou, et al.
Cancer Research Communications|June 16, 2026
Tumor-Associated Platelets Suppress T-Cell Function and Promote Immune Evasion in TNBC via the P-selectin/ P-selectin glycoprotein ligand-1 PathwayMargaret R Smith-Oliver, Deepa Gautam, Grace C Petrarca, et al.
NPJ Breast Cancer|June 2, 2023
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancerAna C Garrido-Castro, Meredith M Regan, Samuel M Niman, et al.
JCO Precision Oncology|January 20, 2022
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation SequencingAdem Albayrak, Ana C Garrido-Castro, Marios Giannakis, et al.
Cancer Research|August 2, 2018
Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast CancerJessalyn M Ubellacker, Ninib Baryawno, Nicolas Severe, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
Pageof 4